Professional
Added to YB: 2025-08-15
Pitch date: 2025-08-13
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+65.72%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$34.2B
Pitch Price
$58.35
Price Target
N/A
Dividend
N/A
EV/EBITDA
10.35
P/E
48.27
EV/Sales
2.92
Sector
Pharmaceuticals
Category
N/A
Pernas Research Passes On: Teva Pharmaceutical Industries Limited
TEVA (pass): Teva Pharma ($16.6, $19B mrkt cap, 7.6x EV/EBITDA) - branded drugs growing 25% annually (Austedo, Ajovy, Uzedy) but unclear if can offset risks: opioid settlements, Copaxone litigation, rebate obligations, generic headwinds (60% of rev) facing price erosion, margin pressure from Medicaid rebate cap removal.
Read full article (1 min)